XML 60 R39.htm IDEA: XBRL DOCUMENT v3.24.3

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Information about Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income

The table below presents information about Edwards Lifesciences' reportable segments (in millions):

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Segment Net Sales
United States			$	804.6					$	735.9					$	2,393.1					$	2,203.6
Europe			315.1						282.7						968.4						878.0
Japan			85.8						84.9						265.6						251.5
Rest of World			153.2						136.1						440.9						399.0
Total segment net sales			$	1,358.7					$	1,239.6					$	4,068.0					$	3,732.1
Segment Operating Income
United States			$	551.2					$	498.4					$	1,619.2					$	1,510.2
Europe			177.3						156.1						540.3						489.2
Japan			54.4						53.7						159.8						158.5
Rest of World			67.2						59.5						184.7						170.6
Total segment operating income			$	850.1					$	767.7					$	2,504.0					$	2,328.5

The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Net Sales Reconciliation
Segment net sales			$	1,358.7					$	1,239.6					$	4,068.0					$	3,732.1
Foreign currency			(4.3)						3.8						(14.3)						11.5
Consolidated net sales			$	1,354.4					$	1,243.4					$	4,053.7					$	3,743.6
Pre-tax Income Reconciliation
Segment operating income			$	850.1					$	767.7					$	2,504.0					$	2,328.5
Unallocated amounts:
Corporate items			(468.7)						(410.1)						(1,396.5)						(1,259.4)
Restructuring expenses (Note 4)			(32.9)						—						(32.9)						—
Intellectual property agreement and certain litigation expenses			(10.8)						(2.2)						(27.8)						(193.6)
Change in fair value of contingent consideration liabilities			—						—						—						26.2
Foreign currency			12.9						10.5						19.3						60.4
Consolidated operating income			350.6						365.9						1,066.1						962.1
Non-operating income			52.2						21.7						91.9						43.1
Consolidated pre-tax income			$	402.8					$	387.6					$	1,158.0					$	1,005.2

Schedule of Enterprise-Wide Information

The following enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Net Sales by Geographic Region
United States			$	804.6					$	735.9					$	2,393.1					$	2,203.6
Europe			319.8						286.5						978.0						877.7
Japan			81.4						85.8						253.9						266.4
Rest of World			148.6						135.2						428.7						395.9
			$	1,354.4					$	1,243.4					$	4,053.7					$	3,743.6
Net Sales by Major Product Group
Transcatheter Aortic Valve Replacement			$	1,023.3					$	960.9					$	3,069.8					$	2,900.4
Transcatheter Mitral and Tricuspid Therapies			91.1						52.4						247.0						141.6
Surgical Structural Heart			240.0						230.1						736.9						701.6
			$	1,354.4					$	1,243.4					$	4,053.7					$	3,743.6

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration